All In Biotech

Free tool

FAERS Monitor: Cystaran

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 200740 or its brand name (Cystaran, Cysteamine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

458

Serious

96

21% of reports

Hospitalization

62

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation141
  • eye pain59
  • ocular hyperaemia54
  • photophobia36
  • product dose omission issue19
  • headache18
  • nausea17
  • vomiting17
  • intentional product misuse13
  • vision blurred13
  • burning sensation11
  • eye pruritus10
  • conjunctivitis9
  • diarrhoea8
  • off label use8

Reports by year received

View as table
YearReports
20131
201412
20157
201635
201774
201862
201970
202083
20216
202223
202325
202428
202531
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,701 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye irritationSignal141112.898.315,513
photophobiaSignal3688.064.33,009
ocular hyperaemiaSignal5452.340.72,670
eye painSignal5948.137.92,677
conjunctivitisSignal922.311.7162
eye pruritusSignal1013.77.4105
burning sensationSignal117.24.053
intentional product misuseSignal136.84.059
vision blurredSignal134.32.530
product dose omission issueSignal193.01.923
vomiting171.71.04
headache181.30.81
nausea171.00.60
diarrhoea80.60.32
off label use80.40.26

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.